Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks

Daiichi Sankyo has selected the first immuno-oncology candidate under its deal with Zymeworks. The action sees Daiichi pay Zymeworks $3.5 million to license an asset based on its bispecific antibody platform.